• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺原发性鳞状细胞癌:一项个体参与者数据的荟萃分析。

Primary squamous cell carcinomas in the thyroid gland: an individual participant data meta-analysis.

作者信息

Cho Jae Keun, Woo Seung-Hoon, Park Junoh, Kim Min-Ji, Jeong Han-Sin

机构信息

Department of Otorhinolaryngology-Head and Neck Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

出版信息

Cancer Med. 2014 Oct;3(5):1396-403. doi: 10.1002/cam4.287. Epub 2014 Jul 4.

DOI:10.1002/cam4.287
PMID:24995699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4302690/
Abstract

Primary squamous cell carcinomas arising from the thyroid gland (SCCTh) is extremely rare diseases, which have never been fully studied. Thus, we performed a systematic review and individual participant data meta-analysis of published SCCTh cases, to understand the clinical characteristics and to identify the prognostic factors of primary SCCTh. A literature search was conducted within Medline, EMBASE, Cochrane library databases and KoreaMed using the following Medical Subject Headings (MeSH) keywords: "primary," "squamous," "carcinoma," "cancer," and "thyroid." Eighty-four patients' individual data from 39 articles and five patients' data in our institute were selected for analysis (N = 89). The mean age at diagnosis was 63.0 years (range, 24-90) and female preponderance (M:F = 1:2) was noted. The commonest complaint was the anterior neck mass, followed by dyspnea or dysphagia, and extension to the adjacent structure was found in 72%. The median survival was 9.0 months (95% CI, 6.0-23.0) and 3-year survival rate (3YSR) was 37.6% by Kaplan-Meier method, but only 20.1% by a shared frailty model for adjusting heterogeneity. Complete resection (R0) of tumors was the only significant prognostic factor in multivariable analysis, and the benefit of adjuvant treatment was not proved. The prognosis of patients with SCCTh is very poor (20% in 3YSR), but complete resection of disease is correlated with improved survival. To achieve complete surgical eradication of tumors, early detection and accurate diagnosis should be emphasized.

摘要

原发性甲状腺鳞状细胞癌(SCCTh)是极为罕见的疾病,此前从未得到充分研究。因此,我们对已发表的SCCTh病例进行了系统综述和个体参与者数据荟萃分析,以了解其临床特征并确定原发性SCCTh的预后因素。使用以下医学主题词(MeSH)关键词在Medline、EMBASE、Cochrane图书馆数据库和KoreaMed中进行文献检索:“原发性”、“鳞状”、“癌”、“癌症”和“甲状腺”。从39篇文章中选取了84例患者的个体数据,并纳入了我们研究所的5例患者数据进行分析(N = 89)。诊断时的平均年龄为63.0岁(范围24 - 90岁),女性占优势(男:女 = 1:2)。最常见的症状是颈前肿块,其次是呼吸困难或吞咽困难,72%的患者出现向邻近结构的侵犯。通过Kaplan-Meier法计算,中位生存期为9.0个月(95%CI,6.0 - 23.0),3年生存率(3YSR)为37.6%,但通过用于调整异质性的共享脆弱模型计算仅为20.1%。多变量分析中,肿瘤的完整切除(R0)是唯一显著的预后因素,辅助治疗的益处未得到证实。SCCTh患者的预后非常差(3YSR为20%),但疾病的完整切除与生存率提高相关。为实现肿瘤的完全手术根除,应强调早期检测和准确诊断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a349/4302690/3827b40fd79c/cam40003-1396-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a349/4302690/daf6179cefef/cam40003-1396-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a349/4302690/3827b40fd79c/cam40003-1396-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a349/4302690/daf6179cefef/cam40003-1396-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a349/4302690/3827b40fd79c/cam40003-1396-f2.jpg

相似文献

1
Primary squamous cell carcinomas in the thyroid gland: an individual participant data meta-analysis.甲状腺原发性鳞状细胞癌:一项个体参与者数据的荟萃分析。
Cancer Med. 2014 Oct;3(5):1396-403. doi: 10.1002/cam4.287. Epub 2014 Jul 4.
2
Primary Squamous Cell Carcinoma in the Thyroid Gland: A Population-Based Analysis Using the SEER Database.甲状腺原发性鳞状细胞癌:基于监测、流行病学和最终结果(SEER)数据库的人群分析
World J Surg. 2019 May;43(5):1249-1255. doi: 10.1007/s00268-019-04906-2.
3
Primary squamous cell carcinoma of thyroid gland: 11 case reports and a population-based study.甲状腺原发性鳞状细胞癌:11 例报告和一项基于人群的研究。
World J Surg Oncol. 2022 Nov 3;20(1):352. doi: 10.1186/s12957-022-02814-9.
4
[Primary squamous cell carcinoma of the thyroid: retrospective analysis of 28 cases].[甲状腺原发性鳞状细胞癌:28例回顾性分析]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Feb;48(2):143-7.
5
Metastasis to the thyroid gland: report of a large series from the Mayo Clinic.甲状腺转移:梅奥诊所的大宗病例报告。
Am J Clin Oncol. 2015 Aug;38(4):338-42. doi: 10.1097/COC.0b013e31829d1d09.
6
Prognostic Characteristics of Primary Squamous Cell Carcinoma of the Thyroid: A National Cancer Database Analysis.甲状腺原发性鳞状细胞癌的预后特征:一项国家癌症数据库分析
World J Surg. 2020 Feb;44(2):348-355. doi: 10.1007/s00268-019-05098-5.
7
The Benefit of Primary Tumor Surgical Resection in Distant Metastatic Carcinomas of the Thyroid.甲状腺远处转移癌行原发灶手术切除的获益。
Laryngoscope. 2021 May;131(5):1026-1034. doi: 10.1002/lary.29053. Epub 2020 Aug 31.
8
Primary squamous cell carcinoma of the thyroid: report of three cases.甲状腺原发性鳞状细胞癌:三例报告
Endocr J. 2008 May;55(2):359-64. doi: 10.1507/endocrj.k07e-102. Epub 2008 Apr 1.
9
Primary squamous cell carcinoma of the thyroid.甲状腺原发性鳞状细胞癌。
Eur J Surg Oncol. 2002 Feb;28(1):42-5. doi: 10.1053/ejso.2001.1180.
10
Squamous cell carcinoma of thyroid gland.甲状腺鳞状细胞癌。
J Assoc Physicians India. 2001 Feb;49:279-80.

引用本文的文献

1
Letter to the Editor: metastatic risk factors in primary squamous cell carcinoma of the thyroid: a call for deeper analysis.致编辑的信:甲状腺原发性鳞状细胞癌的转移危险因素:呼吁进行更深入分析。
Updates Surg. 2025 Aug 12. doi: 10.1007/s13304-025-02357-0.
2
Efficacy of combined immunotherapy and targeted therapy in overcoming barriers to postoperative recurrence in squamous subtype anaplastic thyroid carcinoma with abscess: a case report and literature review.免疫治疗联合靶向治疗克服伴脓肿的鳞状细胞亚型间变性甲状腺癌术后复发障碍的疗效:一例报告及文献综述
Front Oncol. 2025 Mar 19;15:1477954. doi: 10.3389/fonc.2025.1477954. eCollection 2025.
3

本文引用的文献

1
Laryngotracheal presentation of anaplastic thyroid carcinoma with squamous differentiation: seven cases demonstrating an under-recognized diagnostic pitfall.伴有鳞状分化的间变性甲状腺癌的喉气管表现:7例病例揭示一种未被充分认识的诊断陷阱。
Histopathology. 2014 Oct;65(4):501-7. doi: 10.1111/his.12408. Epub 2014 May 12.
2
Anaplastic thyroid carcinoma: a 25-year single-institution experience.间变性甲状腺癌:25年单机构经验
Ann Surg Oncol. 2014 May;21(5):1665-70. doi: 10.1245/s10434-014-3545-5. Epub 2014 Feb 20.
3
Primary squamous cell carcinoma of the thyroid with cardiac metastases and right ventricle outflow tract obstruction.
Risk factors of cervical lymph node metastasis and distant metastasis in patients with primary squamous cell carcinoma of the thyroid: a population-based study.
甲状腺原发性鳞状细胞癌患者颈部淋巴结转移和远处转移的危险因素:一项基于人群的研究。
Updates Surg. 2025 Apr;77(2):401-410. doi: 10.1007/s13304-025-02143-y. Epub 2025 Mar 4.
4
State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.COVID-19时代甲状腺癌的知识现状——一篇综述
Biomedicines. 2024 Dec 13;12(12):2829. doi: 10.3390/biomedicines12122829.
5
Cervical lymph node metastasis as the first symptom of combined anaplastic thyroid carcinoma (squamous cell carcinoma) and follicular carcinoma: a case report.以颈淋巴结转移为首发症状的间变性甲状腺癌(鳞状细胞癌)合并滤泡癌:1例报告
BMC Endocr Disord. 2024 Jun 12;24(1):87. doi: 10.1186/s12902-024-01617-1.
6
Progress in diagnosing and treating thyroid squamous cell carcinoma under the 5th edition of WHO classification.第五版 WHO 分类下甲状腺鳞状细胞癌的诊断和治疗进展。
Front Endocrinol (Lausanne). 2024 Jan 18;14:1273472. doi: 10.3389/fendo.2023.1273472. eCollection 2023.
7
Primary squamous cell carcinoma of thyroid gland: 11 case reports and a population-based study.甲状腺原发性鳞状细胞癌:11 例报告和一项基于人群的研究。
World J Surg Oncol. 2022 Nov 3;20(1):352. doi: 10.1186/s12957-022-02814-9.
8
Primary squamous cell carcinoma of the thyroid treated with concurrent chemoradiation and palliative immunotherapy: a case report.甲状腺原发性鳞状细胞癌经同期放化疗和姑息性免疫治疗:一例报告。
J Med Case Rep. 2022 Oct 5;16(1):364. doi: 10.1186/s13256-022-03596-0.
9
Differences Between Cancer-Specific Survival of Patients With Anaplastic and Primary Squamous Cell Thyroid Carcinoma and Factors Influencing Prognosis: A SEER Database Analysis.间变性和原发性甲状腺鳞状细胞癌患者的癌症特异性生存率差异及预后影响因素:一项监测、流行病学和最终结果(SEER)数据库分析
Front Endocrinol (Lausanne). 2022 Mar 10;13:830760. doi: 10.3389/fendo.2022.830760. eCollection 2022.
10
Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report.达拉非尼与曲美替尼联合治疗BRAF V600E突变型甲状腺原发性鳞状细胞癌的疗效:一例报告
Eur Thyroid J. 2021 Nov;10(6):511-516. doi: 10.1159/000518055. Epub 2021 Sep 3.
甲状腺原发性鳞状细胞癌伴心脏转移及右心室流出道梗阻。
J Clin Oncol. 2012 Sep 10;30(26):e260-3. doi: 10.1200/JCO.2011.39.9808. Epub 2012 May 29.
4
Individual participant data meta-analysis of prognostic factor studies: state of the art?个体参与者数据荟萃分析预后因素研究:现状如何?
BMC Med Res Methodol. 2012 Apr 24;12:56. doi: 10.1186/1471-2288-12-56.
5
Primary squamous cell carcinoma of thyroid: a case report and review of literature.甲状腺原发性鳞状细胞癌:一例病例报告及文献复习
Head Neck Oncol. 2012 Mar 27;4:8. doi: 10.1186/1758-3284-4-8.
6
Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.甲状腺原发性单纯鳞状细胞癌:一例伴有 BRAF 突变病例的报告及组织发生学考虑。
Pathol Int. 2012 Jan;62(1):43-8. doi: 10.1111/j.1440-1827.2011.02745.x.
7
Squamous cell carcinoma of the thyroid gland: primary or secondary disease?甲状腺鳞状细胞癌:原发性还是继发性疾病?
J Laryngol Otol. 2011 Jan;125(1):3-9. doi: 10.1017/S0022215110002070. Epub 2010 Oct 18.
8
Thyroid carcinoma with papillary and squamous features: report of a case with histogenetic considerations.具有乳头状和鳞状特征的甲状腺癌:一例病例报告及其发生机制的考虑。
Pathol Res Pract. 2010 Apr 15;206(4):263-9. doi: 10.1016/j.prp.2009.05.003. Epub 2009 Jun 3.
9
Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002.手术和放射治疗可提高间变性甲状腺癌患者的生存率:1983 - 2002年监测、流行病学及最终结果分析
Am J Clin Oncol. 2008 Oct;31(5):460-4. doi: 10.1097/COC.0b013e31816a61f3.
10
Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.通过惩罚最大似然法在生存数据的个体患者数据荟萃分析中研究试验和治疗的异质性。
Stat Med. 2008 May 20;27(11):1894-910. doi: 10.1002/sim.3161.